News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–16
Matches
16
Sources here
6
Companies here
1
Search results Stored financial headlines

Active search

16 matching headlines

Ticker or company: GDTCMain company stories
Clear
Latest

Stock Titan Earnings

CytoMed Therapeutics Ltd SEC Filing (Aug 11, 2026)

This article reports on CytoMed Therapeutics Ltd's (GDTC) SEC Form 144 filing from August 11, 2026. The filing indicates a proposed sale of securities under Rule 144, detailing information about the issuer, securities to be sold (Ordinary Shares acquired on 04/22/2021), and the transaction details. It also includes general company information, recent news, and other SEC filings.

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingKey Market update Main company 🇺🇸 United States

GDTC|CytoMed Therapeutics Ltd|Price:0.960|Chg%:+0.030

This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its current stock price, market cap, key financial figures, and recent performance. It highlights the company's focus on developing cell-based immunotherapies for cancer, specifically utilizing gamma delta T cell and natural …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for CytoMed Therapeutics Ltd (GDTC), noting that relevant data regarding business segments and regional revenue contributions have not been disclosed by the company. It highlights the current stock price and market capitalization of GDTC. The primary message is …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Market update Main company 🇺🇸 United States

CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), detailing its current support, resistance levels, and the readings from various technical indicators and moving averages. According to the analysis, the overall signal is Neutral based on moving averages and other technical indicators, …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

CytoMed Therapeutics Ltd (GDTC) Institutional Confidence

This article provides an overview of institutional holdings in CytoMed Therapeutics Ltd (GDTC), indicating shareholder activity and changes in shares held by various entities. Key shareholders include Glorious Finance Limited, mDR Limited, and 28 Consultants Ltd, with some showing recent changes in their positions. …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

GDTC|CytoMed Therapeutics Ltd|Price:0.871|Chg%:-0.119

This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its stock performance, key financial indicators, and earnings reports. It presents data from income statements, balance sheets, and cash flow statements, offering insights into the company's revenue, net profit, assets, liabilities, …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CytoMed Therapeutics Ltd (GDTC) Cash Flow

This article provides a detailed overview of CytoMed Therapeutics Ltd's (GDTC) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial data, allowing users to evaluate the company's financial health. The report also defines key cash flow metrics and …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), indicating a "Strong Buy" analyst rating with a target price of USD 5.00, representing a 143.90% upside. It notes that this rating is based on 0 analysts, and relevant financial forecasting data for …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CytoMed Therapeutics Ltd (GDTC) Income Statement

This article provides the income statement for CytoMed Therapeutics Ltd (GDTC), detailing quarterly and annual financial performance from FY2020H1 to FY2024H2. It includes data on revenue, operating expenses, R&D expenses, operating profit, net income, and earnings per share. The piece also offers FAQs on …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

CytoMed Therapeutics (GDTC) director adds 200,000 shares in July buys

CytoMed Therapeutics director and 10% owner Choo Chee Kong purchased 200,000 ordinary shares in July 2026 through two separate transactions at $1.50 per share. An amended Form 4/A corrected the filing to accurately report these as acquisitions rather than dispositions. These trades were not …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com India Regulatory and legal Main company 🇺🇸 United States

Form 4 CytoMed Therapeutics Ltd For: 24 July By Investing.com

This article from Investing.com is a regulatory filing update, announcing the Form 4 for CytoMed Therapeutics Ltd, dated July 24th. The content is primarily a placeholder for the filing details, with additional trending stock data and market summaries provided by the platform. It does …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Market update Main company 🇺🇸 United States

Cytomed director, 10% owner Choo Chee Kong acquires $300,000 in common shares

Cytomed Therapeutics director and 10% owner Choo Chee Kong acquired 200,000 ordinary shares at $1.5 each, totaling $300,000. These transactions increased his direct holding to 630,324 shares. The information was disclosed via the U.S. Securities and Exchange Commission's EDGAR system.

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

CytoMed Therapeutics (GDTC) insider discloses two ordinary share dispositions

CytoMed Therapeutics director and 10% owner Choo Chee Kong reported two non-derivative dispositions of 100,000 ordinary shares each, priced at $1.50 per share, on July 14 and July 20, 2026. These transactions, totaling 200,000 shares sold, were classified as direct ownership, with no post-transaction …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Market update Main company 🇺🇸 United States

CytoMed Therapeutics' US$1.7m Market Cap Fall Books Insider Losses

Insiders at CytoMed Therapeutics, particularly Executive Chairman Chee Kong Choo, are facing losses after the company's market cap fell by US$1.7 million. Despite a recent 14% stock drop, insiders had previously purchased shares at a higher average price, suggesting a continued belief in the …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

CytoMed Therapeutics (GDTC) chair discloses 24.3% share stake

CytoMed Therapeutics Ltd's Chairman and Director, Choo Chee Kong, has filed an amended ownership report revealing he beneficially owns 2,899,746 ordinary shares, representing 24.30% of the company's outstanding shares. His holdings include shares through Glorious Finance Limited, EP Capital Inc., and directly. Between July …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026
FinancialContent Deals and strategy Main company 🇺🇸 United States

CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector

CytoMed Therapeutics Ltd, a clinical-stage biotech company spinning off from ASTAR, is developing affordable cancer therapies using allogeneic Gamma Delta T Cells. The company's strategy involves leveraging lower costs in Southeast Asia, partnering with hospitals, and focusing on markets like China and India, while …

GDTC main company
Sharemaestro market context New activity signal 52 weeks -48.7% GDTC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context